We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
“We have reduced our revenue and EPS estimates for FY21E-FY22E by 4-5 per cent and 12-14 per cent to factor COVID-19 impact and lower other income,” commented the capital market company on the pharma company’s financial performance for the quarter.